Xtandi, a medication developed by Astellas and Pfizer, has been shown to decrease mortality risk in a clinical trial involving prostate cancer patients.
Astellas and Pfizer have released five-year follow-up results from the open-label extension of the Phase III ARCHES trial, which evaluated the effectiveness of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The study, which enrolled 1,150 participants across multiple countries, showed that the combination therapy reduced mortality risk by 30% compared to placebo plus ADT. The findings offer a long-term perspective on the overall survival benefits of Xtandi, an androgen receptor pathway inhibitor.
The results indicated that patients treated with the combination therapy experienced a significant reduction in mortality risk, with a 36-month improvement in median overall survival for those with high-volume disease. The study also assessed various subgroups, including those with low-volume disease and those previously treated with docetaxel, and found consistent survival improvements across all groups.
The occurrence of treatment-emergent adverse events during the five-year follow-up was consistent with previous analyses from the ARCHES trial, with no new safety concerns identified. The study’s primary endpoint was radiographic progression-free survival, with overall survival as a key secondary endpoint. The post hoc five-year analysis aimed to provide a comprehensive view of long-term survival benefits.
Astellas’ executive vice-president, Shontelle Dodson, stated that the collective data for Xtandi continues to reinforce its long-term efficacy and patient impact in prostate cancer, including in the metastatic setting. Xtandi has been approved for use in over 90 countries, including the European Union, Japan, and the US. Astellas is responsible for global manufacturing and commercialization outside the US, while both companies jointly market the therapy within the US.
The results of this study are significant, as they demonstrate the long-term benefits of Xtandi in combination with ADT in men with mHSPC. The reduction in mortality risk and improvement in overall survival are promising findings, and the study’s results are expected to inform treatment decisions for patients with this type of cancer. Additionally, the study’s findings are consistent with previous analyses, which further reinforces the efficacy and safety of Xtandi in this patient population. Overall, the results of this study highlight the importance of Xtandi as a treatment option for men with mHSPC.
Apollo introduces a revolutionary non-surgical treatment for piles, transforming patient care – Healthcare Radius
Apollo Hospitals has introduced a new non-surgical procedure to treat piles, also known as hemorrhoids. This innovative treatment offers a pain-free and minimally invasive solution for patients suffering from this common condition. Piles are swollen blood vessels in the rectal area, causing discomfort, bleeding, and pain during bowel movements.
The new procedure, available at Apollo Hospitals, utilizes cutting-edge technology to treat piles without the need for surgery. This approach is a significant departure from traditional surgical methods, which can be painful and require lengthy recovery times. The non-surgical procedure is quick, taking only a few minutes to perform, and is done on an outpatient basis.
According to medical experts at Apollo, this new treatment is suitable for patients with grade 1, 2, and 3 hemorrhoids. The procedure involves using a specialized device that applies a small, gentle current to the affected area, causing the hemorrhoid to shrink. This technique promotes blood clotting, which eventually leads to the disappearance of the hemorrhoid.
The benefits of this non-surgical procedure are numerous. Patients experience minimal discomfort and can resume their daily activities immediately after the treatment. The procedure is also relatively risk-free, with no reported complications or side effects. Additionally, the treatment is highly effective, with a high success rate in treating piles.
Apollo Hospitals’ decision to introduce this innovative procedure underscores its commitment to providing cutting-edge medical care to its patients. The hospital’s team of experienced doctors and medical professionals are trained to perform this non-surgical procedure, ensuring that patients receive the best possible care.
The introduction of this new procedure is expected to revolutionize the treatment of piles, offering patients a pain-free and minimally invasive solution. With this treatment, patients can say goodbye to the discomfort and pain associated with traditional surgical methods. Apollo Hospitals’ dedication to innovation and patient care has made it a leader in the healthcare industry, and this new procedure is just another example of its commitment to providing exceptional medical care. Overall, the non-surgical procedure for piles is a game-changer, offering a quick, easy, and effective solution for patients suffering from this common condition.
Piramal Pharma’s i-pill Daily campaign empowers women to make educated decisions about their reproductive health.
Piramal Consumer Healthcare has launched a new campaign for its emergency contraceptive pill, i-pill Daily, with the aim of empowering women to take control of their reproductive health and make informed choices. The campaign highlights the importance of insisting on the right brand at the point of purchase, as many women often end up with a substitute due to discomfort and haste during the buying experience. The campaign encourages women to “ask boldly, insist clearly, and choose confidently” when it comes to their reproductive health.
The film, shot in black and white, tackles the outdated discomfort surrounding the purchase of contraceptive products and urges viewers to assert their agency and choose a trusted brand like i-pill Daily. The campaign is built on the idea that every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that the campaign is a reminder to women that their health is too important to be left to chance or compromise.
The campaign aims to address the issue of substitution, where women often end up with a different brand due to social conditioning and embarrassment. Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign plays on the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.
The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets. The campaign is a significant step towards promoting women’s health, dignity, and informed choice, and encouraging women to take control of their reproductive health. By emphasizing the importance of choosing a trusted brand like i-pill Daily, the campaign aims to convert salience into sales at the point of purchase and promote a more empowered and informed approach to women’s healthcare.
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India’s position as a global supplier of generic medicines, leading to increased trade volume and job creation. The sector has shown positive momentum in the short term, reflecting a steady rise in investor confidence. Analysts project substantial upside potential for various companies operating in this space.
Several top companies in the sector have been identified as having strong upside potential. Cohance Lifesciences Limited, a technology-driven contract development and manufacturing organization, has a target price of Rs. 1400.00, indicating an upside potential of 33%. Piramal Pharma Limited, a global pharmaceutical company, has a target price of Rs. 271.00, reflecting an upside potential of 32%. Natco Pharma Limited, a vertically integrated pharmaceutical company, has a target price of Rs. 1090.00, indicating an upside potential of 28%.
Other companies with strong upside potential include Aurobindo Pharma Limited, which has a target price of Rs. 1470.00, reflecting an upside potential of 23%, and Blue Jet Healthcare Limited, which has a target price of Rs. 943.00, indicating an upside potential of 19%. Zydus Lifesciences Limited, a global life sciences company, has a target price of Rs. 1040.00, reflecting an upside potential of 18%.
Overall, the outlook for the Indian pharmaceutical sector remains positive, driven by the new trade agreement with the European Union and the growth potential of various companies operating in the space. Analysts recommend a strong buy for Cohance Lifesciences and Piramal Pharma, a buy for Aurobindo Pharma and Blue Jet Healthcare, and a hold for Natco Pharma and Zydus Lifesciences.
The financial performance of these companies has been strong, with many reporting significant year-on-year sales growth. However, some companies have seen a decline in profit after tax (PAT) due to various factors. Despite this, the long-term implications of the trade agreement and the growth potential of the sector are expected to drive growth and innovation in the Indian pharmaceutical industry.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.